Annette was first appointed to the Board of Directors in September 2017.
In March 2020 she was re-appointed for a further three-year term starting on 1 September 2020 and in March 2023 she was re-appointed for a final three-year term starting on 1 September 2023.
Annette has 35 years of international experience working within the pharmaceutical sector, including at Warner-Lambert, Pfizer and most recently GSK where she was Senior Vice President, Global Head of Product Development and Clinical Supply.
She has been directly involved in the research, development and launch of over 30 new medicines in respiratory, infectious diseases, cancer and inflammatory conditions.
She is currently Senior Adviser at Frazier Life Sciences, a team investing in and building companies developing and commercializing novel therapeutics. She has served on the Boards of various research, educational and charitable organizations including the Association for British Pharmaceutical industry (ABPI) and the Medical Research Council.
In addition to her NED role at CUH, she currently holds Trustee positions at several charities including Addenbrookes Hospital Charitable Trust (ACT), The Royal Society of Chemistry (RSC), St John Ambulance and Tonbridge Grammar School Academy Trust.
She has a BSc in Chemistry and a PhD in Organic Synthesis from Imperial College London and conducted postdoctoral research with a NATO fellowship at Ohio State University.